Do we know everything about anthracyclines in the adjuvant treatment of breast cancer?

Renata Sienkiewicz-Kozłowska, Iwona Głogowska, Dominika Jaxa-Larecka, Tadeusz Pieńkowski

PDF

The role of anthracyclines in the treatment of advanced breast cancer — the place of nonpegylated liposomal doxorubicin

Iwona Głogowska, Roman Dubiański, Anna Skrzypczyk, Tadeusz Pieńkowski

PDF

Posttreatment cardiotoxity in patient with lymphoma

Wojciech Jurczak, Tomasz Ogórka

PDF

Liposomal doxorubicin (Myocet^®) with cyclophosphamide for first-line therapy of metastatic breast cancer in patient previously treated with anthracyclines in the adjuwant setting

Magdalena Kustra, Elżbieta Nowara

PDF

Chemotherapy based on liposomal doxorubicin (Myocet^®) in metastatic breast cancer after prior first-line treatment with anthracycline

Jerzy Hanslik

PDF

First-line treatment of metastatic breast cancer with the use of liposomal doxorubicin (Myocet^®) in a female patient with ischaemic heart disease and cardiac dysrhythmia

Jerzy Hanslik

PDF

The use of liposomal doxorubicin as the next line treatment in metastatic breast cancer

Małgorzata Chudzik

PDF

Efficiency of liposomal doxorubicin in the treatment of advanced breast cancer after completed conventional doxorubicin cumulative dose

Michał Tomala

PDF

Non-pegylated liposomal doxorubicin use in the treatment of bilateral breast cancer

Monika Nowaczyk

PDF

Meningeal carcinomatosis in breast cancer patient — attempt of the treatment with liposomal doxorubicin

Halina Rudnicka, Dorota Wiszniewska-Rawik

PDF

Treatment for advanced metastatic breast cancer, after use the total recommended cumulated dose of doxorubicin

Anna Majstrak, Iwona Głogowska, Izabela Lemańska, Tadeusz Pieńkowski

PDF

The use of liposomal doxorubicin (Myocet^®) in the treatment of advanced breast cancer in 87-year-old woman

Piotr Sawrycki

PDF